Roche's Tecentriq Gets EC Nod As Adjuvant Treatment For Certain People With Early-stage NSCLC

SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG's (RHHBY) blockbuster drug Tecentriq has been approved by the European Commission for yet another lung cancer indication - this time, as an adjuvant

Related Keywords

China , Canada , United Kingdom , Levi Garraway , European Commission , Head Of Global Product Development , Roche Holding , Chief Medical Officer , Global Product , Roche , Tecentriq , Jets , Adjuvant , Treatment , Certain , People , Ith , Early , Stage , Nsclc ,